1. Home
  2. SVV vs GLUE Comparison

SVV vs GLUE Comparison

Compare SVV & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Savers Value Village Inc.

SVV

Savers Value Village Inc.

HOLD

Current Price

$9.03

Market Cap

1.4B

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$11.88

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SVV
GLUE
Founded
1954
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
SVV
GLUE
Price
$9.03
$11.88
Analyst Decision
Buy
Strong Buy
Analyst Count
6
3
Target Price
$13.67
$32.00
AVG Volume (30 Days)
970.0K
1.0M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$1,678,954,000.00
$123,672,000.00
Revenue This Year
$6.91
N/A
Revenue Next Year
$7.80
$2.45
P/E Ratio
$92.60
$72.42
Revenue Growth
9.19
63.54
52 Week Low
$6.91
$6.38
52 Week High
$13.89
$25.77

Technical Indicators

Market Signals
Indicator
SVV
GLUE
Relative Strength Index (RSI) 37.66 N/A
Support Level $8.90 N/A
Resistance Level $10.41 N/A
Average True Range (ATR) 0.36 0.00
MACD -0.08 0.00
Stochastic Oscillator 11.32 0.00

Price Performance

Historical Comparison
SVV
GLUE

About SVV Savers Value Village Inc.

Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second-hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, and sells these items in its stores.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Share on Social Networks: